AstraZeneca and Innate Pharma enter into partnership for the development of CD39 mAbs
On October 23, 2018, Innate Pharma announced that it had entered into a development collaboration and option for further co-development and co-commercialisation with AstraZeneca for its CD39 monoclonal antibody, IPH5201.
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.